FMP
Silverback Therapeutics, Inc.
SBTX
NASDAQ
Inactive Equity
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
5.87 USD
0.06 (1.02%)
Valuation Date:
Nov 9, 2022 12:00 AM
Share Price on Valuation Date
$5.87
Stock Beta
0
Shares Outstanding
93770200